1. FRI0315 Safety, tolerability, pharmacokinetic and pharmacodynamic effects of biib059, a monoclonal antibody targeting bdca2 following intravenous (IV) and subcutaneous (SC) single or multiple doses administration in healthy volounteers (HV) and subjects with active systemic lupus erythematosus (SLE). (12th June 2018) Authors: Barbey, C.; Naik, H.; Musselli, C.; Christmann, R.; Stevenson, L.; Rabah, D.; Gulati, P.; Franchimont, N. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 694 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗